Yarrow Bioscience Inc (YARW) Stock Price & Analysis
Yarrow Bioscience Inc (YARW) closed at USD 20 on Thursday, October 15, 2026, up 5.82% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 18.9; the Oct 15, 2026 session ranged USD 18.85–20.05 on volume of 183,558 shares. Market capitalization is $186.09M, with a 52-week range of USD 16.05–46.95 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/YARW.md
Key facts (YARW)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 57 (range 56–58).
- Total return with dividends: 1Y +96.3% vs S&P 500 +18.1%; 5Y -96.8% vs S&P 500 +85.1%.
Analysts (YARW)
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 57 (low 56, high 58).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-03 | BTIG | Initiated | Buy | $58 |
| 2026-07-28 | TD Cowen | Initiated | Buy |
Total return (dividends reinvested) (YARW)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +96.3% | -96.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +96.8% | -49.6% |
| Volatility (annualized) | 69.1% | 112.0% |
| Max drawdown | -56.7% (Aug 2026→Oct 2026) | -98.9% (Dec 2021→Sep 2025) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 20 |
|---|---|
| Change | ▲ 5.82% (up) |
| Previous Close | USD 18.9 |
| Open | USD 18.85 |
| Day Range | USD 18.85 – 20.05 |
| 52-Week Range | USD 16.05 – 46.95 |
| Volume | 183,558 shares |
| Market Cap | $186.09M |
| Exchange | NCM |
Technical Analysis (YARW)
Nexqual's technical model rates YARW "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 31.26 (neutral) |
| vs SMA50 | Below (USD 30.39) |
| MACD | -3.06 (negative) |
Analyst Ratings (YARW)
Wall Street analysts rate YARW "Buy" based on 3 analysts, with a mean price target of USD 57 (range USD 56–58), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 57 |
| High Target | USD 58 |
| Low Target | USD 56 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (YARW)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (YARW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 1.4 |
| Total Cash | $18.67M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (YARW)
Nexqual rates Yarrow Bioscience Inc's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $19M cash, no debt |
| Cash Flow | Solid — Operating cash flow $560K (TTM) |
| Efficiency | Mixed — No data |
Ownership (YARW)
| Insider Ownership | +2.02% |
|---|---|
| Institutional Ownership | +38.23% |
| Shares Outstanding | 9.30M |
| Float | 1.75M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (YARW)
Yarrow Bioscience Inc is led by Rebecca Velez Frey Pharm.D., President, CEO & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| President, CEO & Director | Rebecca Velez Frey Pharm.D. |
|---|---|
| Chief Financial Officer | Tyler Zeronda (age 39) |
| Chief Operating Officer | Rachael Alford |
Major Backers & Investors (YARW)
Notable institutional backers of Yarrow Bioscience Inc include Adar1 Capital Management, LLC , Staley Capital Advisers, Inc., Nantahala Capital Management, LLC, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Adar1 Capital Management, LLC | 2.21% |
| Staley Capital Advisers, Inc. | 1.93% |
| Nantahala Capital Management, LLC | 1.5% |
| Lynx1 Capital Management Lp | 1.22% |
| Shay Capital LLC | 1.09% |
| Deeter Investments Llp | 0.75% |
| T3 Companies, LLC | 0.71% |
| Braidwell LP | 0.69% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt